Artificial intelligence and classification of mature lymphoid neoplasms
Exploration of Targeted Anti-tumor Therapy · 23.04.2024 · 5 (2) · 332-348
DOI: 10.37349/etat.2024.00221 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Exploration of Targeted Anti-tumor Therapy, online erschienen am 23.04.2024. Verfasst von Joaquim Carreras und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Tokai University School of Medicine, Isehara 259-1193, Japan. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Hematologists, geneticists, and clinicians came to a multidisciplinary agreement on the classification of lymphoid neoplasms that combines clinical features, histological characteristics, immunophenotype, and molecular pathology analyses. The current classification includes the World Health Organization (WHO) Classification of tumours of haematopoietic and lymphoid tissues revised 4th edition, the International Consensus Classification (ICC) of mature lymphoid neoplasms (report from the Clinical Advisory Committee 2022), and the 5th edition of the proposed WHO Classification of haematolymphoid tumours (lymphoid neoplasms, WHO-HAEM5). This article revises the recent advances in the classification of mature lymphoid neoplasms. Artificial intelligence (AI) has advanced rapidly recently, and its role in medicine is becoming more important as AI integrates computer science and datasets to make predictions or classifications based on complex input data. Summarizing previous research, it is described how several machine learning and neural networks can predict the prognosis of the patients, and classified mature B-cell neoplasms. In addition, new analysis predicted lymphoma subtypes using cell-of-origin markers that hematopathologists use in the clinical routine, including CD3, CD5, CD19, CD79A, MS4A1 (CD20), MME (CD10), BCL6, IRF4 (MUM-1), BCL2, SOX11, MNDA, and FCRL4 (IRTA1). In conclusion, although most categories are similar in both classifications, there are also conceptual differences and differences in the diagnostic criteria for some diseases. It is expected that AI will be incorporated into the lymphoma classification as another bioinformatics tool.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Tokai University School of Medicine, Isehara 259-1193, Japan.
- Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.
- Division of Surgery and Interventional Science, University College London, WC1E 6BT London, UK.
ORCID-Profile: Joaquim Carreras, Rifat Hamoudi, Naoya Nakamura
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Carreras, J., Hamoudi, R., & Nakamura, N. (2024). Artificial intelligence and classification of mature lymphoid neoplasms. Exploration of Targeted Anti-tumor Therapy, 5(2), 332-348. https://doi.org/10.37349/etat.2024.00221
Vancouver
Carreras J, Hamoudi R, Nakamura N. Artificial intelligence and classification of mature lymphoid neoplasms. Exploration of Targeted Anti-tumor Therapy. 2024;5(2):332-348. doi:10.37349/etat.2024.00221
BibTeX
@article{Carreras2024,
author = {Carreras, Joaquim and Hamoudi, Rifat and Nakamura, Naoya},
title = {Artificial intelligence and classification of mature lymphoid neoplasms},
journal = {Exploration of Targeted Anti-tumor Therapy},
year = {2024},
volume = {5},
number = {2},
pages = {332--348},
doi = {10.37349/etat.2024.00221}
}
EUVIMED